Erigo®Pro Coma Outcome Study - Study on the Effectiveness of a Robotic Tilt Table Device for Recovery of Consciousness (EriCOS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02639481|
Recruitment Status : Recruiting
First Posted : December 24, 2015
Last Update Posted : December 12, 2018
|Condition or disease||Intervention/treatment||Phase|
|Brain Injuries Disorders of Consciousness||Behavioral: Standard physiotherapy Device: Erigo®Pro group without FES Device: Erigo®Pro group with FES||Phase 3|
Patients with acquired brain injury (ABI) often suffer from severe disorders of consciousness (DOC), such as coma, unresponsive wakefulness syndrome (UWS), or minimally conscious state (MCS). These DOC can be temporary or persistent. Verticalization and multisensory stimulation are traditionally important therapeutic principles in the neurorehabilitation of such patients. These principles have not yet been tested in randomized controlled trials yet. This trial will therefore evaluate the effect that a 4 week training with a verticalization device (the Erigo®Pro system) with integrated repetitive robotic leg movements and functional electrical stimulation of the leg muscles (FES) has on the clinical course of DOC patients in an inpatient neurorehabilitation setting, following acute ABI. 156 patients will be randomized 1:1:1 to one of the following groups: (i) control group without the Erigo®Pro, (ii) treatment with the Erigo®Pro without FES, and (iii) treatment with the Erigo®Pro and simultaneous FES. There will be 4 training sessions per week for 4 weeks with each session being 60 minutes in length. This will be part of the standard neurorehabilitation program, which in Germany comprises 300 minutes of therapy per day. Patients in the active treatment groups ii) and iii) are required to be verticalized above 60° for at least 35 minutes per treatment session. Patients in the control group will be treated with conventional methods, including verticalization by therapists but without the help of the device. FES will be conducted with the following parameters: 8 channels covering the major ventral and dorsal muscles of the upper and lower, initial current 10 milli ampere (mA), pulse with 250 micro seconds (µs), frequency 25 herz (Hz), ramp 3. Current will be gradually increased to the motor threshold plus 20%.
The investigators will test the following hypotheses:
- Treatment with the Erigo®Pro system will lead to a quicker recovery of consciousness (increase of at least one diagnostic category of the CRS-R) than conventional therapy,
- Treatment with the Erigo®Pro system including FES will lead to a quicker recovery of consciousness than using the Erigo®Pro without FES, 3).) Treatment with the Erigo®Pro system will decrease spasticity and complications of neurorehabilitation (pneumonia, pressure ulcers) than conventional therapy, and
4.) Treatment with the Erigo®Pro system will lead to an improved longterm patient outcome (6 months) with regard to independence in the activities of daily living, compared to conventional therapy.
The main outcome variable is the Coma Recovery Scale - revised (CRS-R), secondary variables are the Functional Independence Measure (FIM), the Nociception Coma Scale (NCS), the Modified Ashworth Scale for spasticity, and quantitative HD-EEG measures for brain activity (power, variability, entropy).
Study visits will be prior to first treatment (t0), during the first treatment in vertical position (t1), directly following the first treatment in horizontal patient positioning (t2), 2 weeks after the first treatment (halfway through treatment protocol, t3), at the end of the final treatment after weeks (t4), and final outcome measurement, 6 months after the patient inclusion (t5) within the patients living environment (nursing home or home).
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||156 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Erigo®Pro Coma Outcome Study - Study on the Effectiveness of a Robotic Tilt Table Device for Recovery of Consciousness|
|Study Start Date :||January 2016|
|Estimated Primary Completion Date :||March 2019|
|Estimated Study Completion Date :||March 2019|
Active Comparator: Control group standard physiotherapy
Patients will receive standard physiotherapy for 60 minutes, including the goal of verticalization and stimulation of the patient but without the use of the robotic Erigo®Pro device.
Behavioral: Standard physiotherapy
Classical standard physiotherapy, including measures to verticalize patients by means of orthesis, classical tilt tables, or castings
Active Comparator: Erigo®Pro group without FES
Patients will receive 60 minutes of therapy with the robotic Erigo®Pro verticalization device but without functional electrical stimulation (FES) of the leg muscles.
Device: Erigo®Pro group without FES
Use of the Erigo®Pro device to verticalize patients to above 60° while performing robotic stepping leg movements. FES ist not used.
Active Comparator: Erigo®Pro group with FES
Patients will receive 60 minutes of therapy with the robotic Erigo®Pro verticalization device including functional electrical stimulation (FES) of the leg muscles.
Device: Erigo®Pro group with FES
Use of the Erigo®Pro device to verticalize patients to above 60° while performing robotic stepping leg movements. FES is applied during then whole treatment session, providing electrical stimulation to the muscles of the upper and lower leg, synchronous to the robotic stepping movements
- Time to recovery of consciousness [ Time Frame: 4 weeks ]Time to improve 1 diagnostic consciousness category in the Coma Recovery Scale - Revised (CRS-R)
- Independence in the activities of daily living [ Time Frame: 6 months ]How independent are patients 6 months after study inclusion, measured by the Functional Independence Measure (FIM)
- Degree of spasticity [ Time Frame: 4 weeks ]Degree of spasticity, measured with the modified Ashworth Scale (mAS)
- Occurrence of typical neurorehabilitation complications [ Time Frame: 4 weeks ]Do pneumonias and pressure ulcers occur in a patient (clinical observation)?
- Change in bioelectrical brain activity [ Time Frame: 4 weeks ]Does treatment lead to increased bioelectrical brain activity, measured by high density EEG (power, variability, entropy)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02639481
|Contact: Andreas Bender, Prof.Dr.||+49894400 ext firstname.lastname@example.org|
|Contact: Marion Arndt||+498222404 ext email@example.com|
|Burgau, Bayern, Germany, 89331|
|Contact: Andreas Bender, MD|
|Principal Investigator: Andreas Bender, MD|
|Department of Neurology, University of Munich||Active, not recruiting|
|Munich, Bayern, Germany, 81377|
|Principal Investigator:||Andreas Bender, Prof.Dr.||Ludwig-Maximilians - University of Munich|